John Climaco News Today

Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ETHOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...

Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in first half of 2025Clinical progress represents important steps towa...

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights ...

01.04.2024 - Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in ... Seite 1

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially ...

Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (CNS or the Company), a biopharmaceutical company specializing in the development of novel t...

CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy ...

Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months.

HOUSTON - CNS Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system,...